Pharmacokinetic Comparison of Sublingual Lorazepam with Intravenous, Intramuscular, and Oral Lorazepam
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Ten healthy volunteers received single 2-mg doses of lorazepam on five occasions in random sequence. Modes of administration were: A, intravenous injection; B, deltoid intramuscular injection; C, oral tablets in the fasting state; D, sublingual dosage of oral tablets in the fasting state; and E, sublingual dosage of specially formulated tablets in the fasting state. Kinetic variables were determined from multiple plasma lorazepam concentrations measured during 48 hr postdose. After intravenous lorazepam, mean (+/- SE) values were: elimination half-life (t 1/2 beta), 12.9 (+/- 0.8) hr; volume of distribution, 1.3 (+/- 0.07) liters/kg; total clearance, 1.21 (+/- 0.1) ml/min/kg. Absorption of intramuscular lorazepam was rapid. Peak plasma levels were reached at 1.15 hr after dosage, with absorption half-life averaging 14.2 (+/- 4.7) min. Absorption or oral and sublingual lorazepam tended to be less rapid than intramuscular injection, although differences were not significant. Times of peak concentration were 2.37, 2.35, and 2.25 hr postdose for trials C,D, and E, respectively; values of absorption half-life were 32.5, 28.5, and 28.7 min. Absolute systemic availability for trials B, C, D, and E averaged 95.9, 99.8, 94.1, and 98.2%, respectively; none of these differed significantly from 100%. Values of t1/2 beta were highly replicable within individuals regardless of the administration route. Thus, sublingual lorazepam is completely absorbed and is a suitable administration route in clinical practice.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Lorazepam | Glucuronidation (24) | NA | 7-26 (39, 40) | NA”
From Benzodiazepines in epilepsy: Pharmacology and pharmacokinetics (2008) · cites this paper as [40]
Citations
Cites
Clinical Pharmacokinetics of Oxazepam and Lorazepam
Greenblatt, D. J. (1981) · Clinical Pharmacokinetics · doi:10.2165/00003088-198106020-00001 · Cited by 367
Self-citationOxazepam kinetics: effects of age and sex.
Greenblatt, D. J., Divoll, M., Harmatz, J. S., & Shader, R. I. (1980) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)32259-7 · Cited by 209
Self-citationPharmacokinetics and bioavailability of intravenous, intramuscular, and oral lorazepam in humans
Greenblatt, D. J., Shader, R. I., Franke, K., MacLaughlin, D. S., Harmatz, J. S., Allen, M. D., Werner, A., & Woo, E. (1979) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600680119 · Cited by 197
Self-citationLorazepam kinetics in the elderly
Greenblatt, D. J., Allen, M. D., Locniskar, A., Harmatz, J. S., & Shader, R. I. (1979) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1979261103 · Cited by 154
Self-citationCimetidine spares the glucuronidation of lorazepam and oxazepam
Patwardhan, R. V., Yarborough, G. W., Desmond, P. V., Johnson, R. F., Schenker, S., & Speeg, K. V. (1980) · Gastroenterology · doi:10.1016/0016-5085(80)90450-3 · Cited by 126
Analysis of lorazepam and its glucoronide metabolite by electron-capture gas—liquid chromatography
Greenblatt, D. J., Franke, K., & Shader, R. I. (1978) · Journal of Chromatography B Biomedical Sciences and Applications · doi:10.1016/s0378-4347(00)81896-4 · Cited by 99
Self-citationAmeer, B., & Greenblatt, D. J. (1981) · Drugs · doi:10.2165/00003495-198121030-00001 · Cited by 88
Self-citationSingle- and multiple-dose kinetics of oral lorazepam in humans: The predictability of accumulation
Greenblatt, D. J., ALLEN, M. D., MacLaughlin, D. S., Huffman, D. H., Harmatz, J. S., & Shader, R. I. (1979) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01059736 · Cited by 42
Self-citation
Research works printed but not linked: 2
- Greenblatt, 1980, J. Pharmacol. Exp. Ther., 215, 86
- Kraus, 1978, ibid., 24, 411
Cited by
Benzodiazepines in epilepsy: Pharmacology and pharmacokinetics
Riss, J., Cloyd, J., Gates, J., & Collins, S. (2008) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2008.01004.x · Cited by 511
Current Status of Benzodiazepines
Koch-Weser, J., Greenblatt, D. J., Shader, R. I., & Abernethy, D. R. (1983) · New England Journal of Medicine · doi:10.1056/nejm198308183090705 · Cited by 451
Self-citationA comparison of rectal diazepam gel and placebo for acute repetitive seizures
Dreifuss, F. E., Rosman, N. P., Cloyd, J. C., Pellock, J. M., Kuzniecky, R. I., Lo, W. D., Matsuo, F., Sharp, G. B., Conry, J. A., Bergen, D. C., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199806253382602 · Cited by 287
Pharmacological Management of Acute Agitation
Battaglia, J. (2005) · Drugs · doi:10.2165/00003495-200565090-00003 · Cited by 254
Current Status of Benzodiazepines
Koch-Weser, J., Greenblatt, D. J., Shader, R. I., & Abernethy, D. R. (1983) · New England Journal of Medicine · doi:10.1056/nejm198308113090607 · Cited by 249
Self-citationBarr, J., Zomorodi, K., Bertaccini, E. J., Shafer, S. L., & Geller, E. (2001) · Anesthesiology · doi:10.1097/00000542-200108000-00007 · Cited by 209
Sedation in the intensive care unit
Young, C., Knudsen, N., Hilton, A., & Reves, J. G. (2000) · Critical Care Medicine · doi:10.1097/00003246-200003000-00041 · Cited by 188
Weinstein, S. M., Poultsides, L., Baaklini, L. R., Mörwald, E. E., Cozowicz, C., Saleh, J. N., Arrington, M. B., Poeran, J., Zubizarreta, N., & Memtsoudis, S. G. (2018) · British Journal of Anaesthesia · doi:10.1016/j.bja.2017.12.046 · Cited by 173
Abduljalil, K., Cain, T., Humphries, H., & Rostami‐Hodjegan, A. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.058099 · Cited by 158
Kienitz, R., Kay, L., Beuchat, I., Gelhard, S., von Brauchitsch, S., Mann, C., Lucaciu, A., Schäfer, J.-H., Siebenbrodt, K., Zöllner, J.-P., et al. (2022) · CNS Drugs · doi:10.1007/s40263-022-00940-2 · Cited by 139
“The duration of action is about 10–20 h and the elimination half-life is 8–25 h [39, 40].”
BackgroundMaharaj, A. R., Barrett, J. S., & Edginton, A. N. (2013) · The AAPS Journal · doi:10.1208/s12248-013-9451-0 · Cited by 128
Understanding the pharmacokinetics of anxiolytic drugs
Altamura, A. C., Moliterno, D., Paletta, S., Maffini, M., Mauri, M. C., & Bareggi, S. R. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.759209 · Cited by 127
Benzodiazepine Poisoning Clinical and Pharmacological Considerations and Treatment
Gaudreault, P., Guay, J. M. Y., Thivierge, R., & Verdy, I. (1991) · Drug Safety · doi:10.2165/00002018-199106040-00003 · Cited by 102
Patterns of benzodiazepine underdosing in the Established Status Epilepticus Treatment Trial
Sathe, A. G., Underwood, E., Coles, L. D., Elm, J., Silbergleit, R., Chamberlain, J. M., Kapur, J., Cock, H. R., Fountain, N. B., Shinnar, S., et al. (2021) · Epilepsia · doi:10.1111/epi.16825 · Cited by 96
Reduced clearance of triazolam in old age: relation to antipyrine oxidizing capacity.
Greenblatt, D., Divoll, M., Abernethy, D., Moschitto, L., Smith, R., & Shader, R. (1983) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1983.tb01503.x · Cited by 92
Self-citationCurrent oral and non-oral routes of antiepileptic drug delivery
Anderson, G. D., & Saneto, R. P. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.01.017 · Cited by 88
Diazepam in the Treatment of Moderate to Severe Alcohol Withdrawal
Weintraub, S. J. (2017) · CNS Drugs · doi:10.1007/s40263-016-0403-y · Cited by 96
Rectal Diazepam Gel for Treatment of Acute Repetitive Seizures in Adults
Cereghino, J. J. (2002) · Archives of Neurology · doi:10.1001/archneur.59.12.1915 · Cited by 81
BENZODIAZEPINES IN THE INTENSIVE CARE UNIT
Young, C. C., & Prielipp, R. C. (2001) · Critical Care Clinics · doi:10.1016/s0749-0704(05)70183-4 · Cited by 75
Metabolism of Anxiolytics and Hypnotics: Benzodiazepines, Buspirone, Zoplicone, and Zolpidem
Chouinard, G., Lefko-Singh, K., & Teboul, E. (1999) · Cellular and Molecular Neurobiology · doi:10.1023/a:1006943009192 · Cited by 87
The behaviour of a fast-dissolving dosage form (Expidet) followed by γ-scintigraphy
WILSON, C. G., Washington, N., Peach, J. M., Murray, G. R., & Kennerley, J. R. (1987) · International Journal of Pharmaceutics · doi:10.1016/0378-5173(87)90056-1 · Cited by 71
A double-blind comparison of lorazepam and oxazepam in psychomotor retardation and mutism
Schmider, J., Standhart, H., Deuschle, M., Drancoli, J., & Heuser, I. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00312-6 · Cited by 75
Understanding the Oral Mucosal Absorption and Resulting Clinical Pharmacokinetics of Asenapine
Bartlett, J. A., & Maarschalk, K. V. D. V. (2012) · AAPS PharmSciTech · doi:10.1208/s12249-012-9839-7 · Cited by 69
“While there are classic examples such as nitroglycerin which do display a short time for maximum plasma concentration (Tmax) following sublingual administration, there are also examples such as lorazepam which display a (Tmax) of almost 2 h (1,2).”
InfluentialRectal diazepam gel for treatment of acute repetitive seizures
Kriel, R. L., Cloyd, J. C., Pellock, J. M., Mitchell, W. G., Cereghino, J. J., & Rosman, N. P. (1999) · Pediatric Neurology · doi:10.1016/s0887-8994(98)00156-8 · Cited by 68
Howard, P., Twycross, R., Shuster, J., Mihalyo, M., & Wilcock, A. (2014) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2014.03.001 · Cited by 64
Physical and Chemical Restraints
Coburn, V. A., & Mycyk, M. B. (2009) · Emergency Medicine Clinics of North America · doi:10.1016/j.emc.2009.07.003 · Cited by 59
VIOLENT PATIENTS IN THE EMERGENCY SETTING
Citrome, L., & Volavka, J. (1999) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(05)70126-x · Cited by 59
Ye, M., Nagar, S., & Korzekwa, K. (2016) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.1996 · Cited by 53
Pharmacological Management of Acute and Persistent Aggression in Forensic Psychiatry Settings
Citrome, L., & Volavka, J. (2011) · CNS Drugs · doi:10.2165/11596930-000000000-00000 · Cited by 54
Management of the Violent Patient
Rice, M., & Moore, G. P. (1991) · Emergency Medicine Clinics of North America · doi:10.1016/s0733-8627(20)30202-9 · Cited by 51
Benzodiazepines in panic disorder and agoraphobia
Sheehan, D. V. (1987) · Journal of Affective Disorders · doi:10.1016/0165-0327(87)90021-8 · Cited by 48
Deguchi, T., Watanabe, N., Kurihara, A., Igeta, K., Ikenaga, H., Fusegawa, K., Suzuki, N., Murata, S., Hirouchi, M., Furuta, Y., et al. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.037457 · Cited by 52
Enhanced Bioavailability of Triazolam Following Sublingual Versus Oral Administration
Scavone, J. M., Greenblatt, D. J., Friedman, H. L., & Shader, R. I. (1986) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1986.tb02935.x · Cited by 46
Self-citationAtypical antipsychotics for acute agitation
Citrome, L. (2002) · Postgraduate Medicine · doi:10.3810/pgm.2002.12.1369 · Cited by 44
Rational Therapeutic Drug Monitoring
Friedman, H. L., & Greenblatt, D. J. (1986) · JAMA · doi:10.1001/jama.1986.03380160085025 · Cited by 42
Strategies for Optimizing Antiepileptic Drug Therapy in Elderly People
Lackner, T. E. (2002) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.22.5.329.33192 · Cited by 43
Citrome, L. (2004) · Psychiatric Quarterly · doi:10.1023/b:psaq.0000031791.53142.85 · Cited by 38
Fosphenytoin: Pharmacokinetics and Tolerance of Intramuscular Loading Doses
Pryor, F. M., Gidal, B. E., Ramsay, R. E., DeToledo, J. C., & Morgan, R. O. (2001) · Epilepsia · doi:10.1046/j.1528-1157.2001.20800.x · Cited by 38
Herman, R. A., & Veng‐Pedersen, P. (1994) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600830332 · Cited by 38
Use of Emergency Medication in Adult Patients with Epilepsy: A Multicentre Cohort Study from Germany
Kadel, J., Bauer, S., Hermsen, A., Immisch, I., Kay, L., Klein, K. M., Knake, S., Menzler, K., Reif, P. S., Rosenow, F., et al. (2018) · CNS Drugs · doi:10.1007/s40263-018-0544-2 · Cited by 39
Lorazepam in catatonia – Past, present and future of a clinical success story
Hirjak, D., Fricchione, G., Wolf, R. C., & Northoff, G. (2024) · Schizophrenia Research · doi:10.1016/j.schres.2023.02.015 · Cited by 36
Clinical Pharmacokinetics of Drugs Administered Buccally and Sublingually
Motwani, J. G., & Lipworth, B. J. (1991) · Clinical Pharmacokinetics · doi:10.2165/00003088-199121020-00001 · Cited by 36
Trends in the management of alcohol withdrawal syndrome
Newman, J. P., Terris, D. J., & Moore, M. (1995) · The Laryngoscope · doi:10.1288/00005537-199501000-00004 · Cited by 36
Veng‐Pedersen, P., & Gillespie, W. R. (1986) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600751202 · Cited by 35
Pharmacologic Management of the Agitated Child
Marzullo, L. R. (2014) · Pediatric Emergency Care · doi:10.1097/pec.0000000000000112 · Cited by 33
Berton, M., Bettonte, S., Stader, F., Battegay, M., & Marzolini, C. (2022) · Clinical Pharmacokinetics · doi:10.1007/s40262-022-01194-3 · Cited by 36
Gillespie, W. R., & Veng‐Pedersen, P. (1985) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01061479 · Cited by 32
“9-217 Lorazepam (21, 22) 17 2-4 243 • 257 4.”
BackgroundBuccal midazolam for pediatric convulsive seizures: efficacy, safety, and patient acceptability
Anderson, M. (2013) · Patient Preference and Adherence · doi:10.2147/ppa.s39233 · Cited by 32
New Non-Intravenous Routes for Benzodiazepines in Epilepsy: A Clinician Perspective
Mula, M. (2016) · CNS Drugs · doi:10.1007/s40263-016-0398-4 · Cited by 32
40 Hz Steady-State Response in Human Auditory Cortex Is Shaped by Gabaergic Neuronal Inhibition
Toso, A., Wermuth, A. P., Arazi, A., Braun, A., Grent-‘t-Jong, T., Uhlhaas, P. J., & Donner, T. H. (2024) · Journal of Neuroscience · doi:10.1523/jneurosci.2029-23.2024 · Cited by 37
Charalambous, M., Volk, H. A., Ham, L. V., & Bhatti, S. F. M. (2021) · BMC Veterinary Research · doi:10.1186/s12917-021-02805-0 · Cited by 40
Scavone, J. M., Greenblatt, D. J., Goddard, J. E., Friedman, H. L., Harmatz, J. S., & Shader, R. I. (1992) · European Journal of Clinical Pharmacology · doi:10.1007/bf00280132 · Cited by 29
Self-citationKaputu-Kalala-Malu, C., Kahamba, D. M., Walker, T. D., Mukampunga, C., Musalu, É. M., Kokolomani, J., Mayamba, R. M. K., Wilmshurst, J. M., Dubru, J.-M., & Misson, J. (2013) · Journal of Child Neurology · doi:10.1177/0883073813493501 · Cited by 33
“Sublingual lorazepam is absorbed slowly compared to other administration routes (intravenous, intramuscular, and intranasal), but after the first 30 minutes, pharmacokinetic profiles are not different(12,21) although it is possible to find differences in lorazepam serum concentrations after its administration by diffe…”
BackgroundBenzodiazepines for prolonged seizures
Anderson, M. (2010) · Archives of Disease in Childhood Education & Practice · doi:10.1136/adc.2009.176321 · Cited by 32
Garnett, W. R., Barr, W. H., Edinboro, L. E., Karnes, H. T., Mesa, M., & Wannarka, G. L. (2010) · Epilepsy Research · doi:10.1016/j.eplepsyres.2010.10.001 · Cited by 29
A Guide to Benzodiazepine Selection. Part I: Pharmacological Aspects *
Teboul, E., & Chouinard, G. (1990) · The Canadian Journal of Psychiatry · doi:10.1177/070674379003500811 · Cited by 28
“et al (43) found that the sublingual formulation was absorbed at a rate that did not differ significantly from regular oral administration of the standard tablets, or even from sublingual administration of the standard oral tablets.”
BackgroundPharmacokinetics of buccal and intranasal lorazepam in healthy adult volunteers
Anderson, M., Tambe, P., Sammons, H. M., Mulla, H., Cole, R., & Choonara, I. (2011) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-011-1109-1 · Cited by 28
Design and Evaluation of a Lorazepam Transdermal Delivery System
Costa, P. C., Ferreira, D., Morgado, R., & Lobo, J. M. S. (1997) · Drug Development and Industrial Pharmacy · doi:10.3109/03639049709149144 · Cited by 26
Clinical practice: The treatment of acute convulsive seizures in children
Lagae, L. G. (2011) · European Journal of Pediatrics · doi:10.1007/s00431-011-1403-z · Cited by 26
Veng‐Pedersen, P., & Gillespie, W. R. (1987) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01066323 · Cited by 25
“The validity of Eq. ( 29 ), is now made clear by substituting Eqs (All) and (A12) into it to give an equation identical to the defining Eq. (17) for FArO However, it must be emphasized that Eqs.”
BackgroundMethodDiphenhydramine kinetics following intravenous, oral, and sublingual dimenhydrinate administration
Scavone, J. M., Luna, B. G., Harmatz, J. S., Moltke, L. L. V., & Greenblatt, D. J. (1990) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.2510110302 · Cited by 23
Self-citationConnemann, B. J., Mann, K., Lange‐Asschenfeldt, C., Ruchsow, M., Schreckenberger, M., Bartenstein, P., & Gründer, G. (2005) · Clinical Neurophysiology · doi:10.1016/j.clinph.2004.11.015 · Cited by 26
Absorption of diazepam and lorazepam following intranasal administration
Lau, S. W. J., & Slattery, J. T. (1989) · International Journal of Pharmaceutics · doi:10.1016/0378-5173(89)90337-2 · Cited by 23
Out‐of‐hospital treatment of status epilepticus and prolonged seizures
Lowenstein, D. H., & Cloyd, J. C. (2007) · Epilepsia · doi:10.1111/j.1528-1167.2007.01363.x · Cited by 21
Optimizing drug treatment of alcohol withdrawal
Rosenbloom, A. J. (1986) · The American Journal of Medicine · doi:10.1016/0002-9343(86)90366-9 · Cited by 20
Management of Violence in Schizophrenia
Citrome, L., & Volavka, J. (2000) · Psychiatric Annals · doi:10.3928/0048-5713-20000101-11 · Cited by 19
Psychopharmacology of Violence: Part I: Assessment and Acute Treatment
Citrome, L., & Volavka, J. (1997) · Psychiatric Annals · doi:10.3928/0048-5713-19971001-10 · Cited by 17
Nonenteral Routes of Administration for Psychiatric Medications
Thompson, D. S., & DiMartini, A. (1999) · Psychosomatics · doi:10.1016/s0033-3182(99)71234-x · Cited by 16
McInnes, F. J., Clear, N., James, G., Stevens, H. N. E., Vivanco, U., & Humphrey, M. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9423-0 · Cited by 15
Yang, Z., Sotthivirat, S., Wu, Y., Lalloo, A., Nissley, B. P., Manser, K., & Li, H. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.02.033 · Cited by 15
“…humans were comparable with oral administration with similar bioavailability (99% and 95%, respectively) and Tmax (2.37 and 2.35 h, respectively) (Greenblatt et al., 1982) The low solubility of lorazepam and its clinical pharmacokinetics indicate that intestinal absorption is the major…”
BackgroundInfluentialBenzodiazepines used Primarily for Emergency Treatment (Diazepam, Lorazepam and Midazolam)
Trinka, E. (2009) · Wiley eBooks · doi:10.1002/9781444316667.ch34 · Cited by 16
Clinical Pharmacology of Benzodiazepines
Klotz, U. E. (1984) · Progress in clinical biochemistry and medicine · doi:10.1007/978-3-642-69872-9_3 · Cited by 15
Neuropharmacology and Drug Interactions in Clinical Practice
Graves, N. M. (1995) · Epilepsia · doi:10.1111/j.1528-1157.1995.tb05997.x · Cited by 14
Chronotherapy in the treatment of epilepsy
Carney, P. R., Stanley, D. A., & Talathi, S. S. (2014) · ChronoPhysiology and Therapy · doi:10.2147/cpt.s54530 · Cited by 16
Buccal midazolam for agitation on psychiatric intensive care wards
Taylor, D. M., Okocha, C. I., Paton, C., Smith, S., & Connolly, A. (2008) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651500802233886 · Cited by 13
The dangerous agitated patient: What to do right now
Citrome, L., & Green, L. (1990) · Postgraduate Medicine · doi:10.1080/00325481.1990.11704569 · Cited by 14
Palliative care and AIDS: 2 - Gastrointestinal symptoms
Meyer, M. (1999) · International Journal of STD & AIDS · doi:10.1177/095646249901000802 · Cited by 12
Comparison of sublingual lorazepam with intramuscular diazepam as sedatives during oral surgery
van der Bijl, P., ROELOFSE, J. A., & Joubert, J. J. D. V. (1988) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/0278-2391(88)90145-0 · Cited by 11
Sublingual lorazepam as rescue therapy for seizure emergencies in adults
Lelis, I. R., & Krauss, G. L. (2023) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2023.109294 · Cited by 12
Tsang, D. S., Voncken, F. E. M., Tse, R. V., Sykes, J. R., Wong, R. K. S., Dinniwell, R. E., Kim, J., Ringash, J. G., Brierley, J. D., Cummings, B., et al. (2013) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2013.08.024 · Cited by 10
“Because lorazepam has a duration of action of 6 to 8 hours and an elimination half-life of 13 to 16 hours (20, 21), the sedating effects of lorazepam were temporary and self-limited.”
BackgroundInfluentialNONCONVENTIONAL DRUG ADMINISTRATION IN ANESTHESIA
Zandsberg, S., & Rosenblum, M. (1994) · Anesthesiology Clinics of North America · doi:10.1016/s0889-8537(21)00721-5 · Cited by 10
Pharmacokinetics and Clinical Effects of Sublingual Triazolam in Pediatric Dental Patients
Tweedy, C. M., Milgrom, P., Kharasch, E. D., Kaakko, T., Spieker, M., & Coldwell, S. E. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200106000-00004 · Cited by 9
Landry, P., Gervais, M., & O’Connor, K. P. (2008) · Annales Médico-psychologiques revue psychiatrique · doi:10.1016/j.amp.2008.06.008 · Cited by 17
Chin, R. (2014) · Epileptic Disorders · doi:10.1684/epd.2014.0684 · Cited by 10
Lissauer, S., Kenny, J. M., Jefferis, O., Wingfield, T., Miller, A., Chagaluka, G., Kalilani‐Phiri, L., & MOLYNEUX, E. M. (2015) · African Journal of Emergency Medicine · doi:10.1016/j.afjem.2015.03.001 · Cited by 9
Vinckenbosch, F. R. J., Vermeeren, A., Vuurman, E. F. P. M., van der Sluiszen, N. N. J. J. M., Verster, J. C., van de Loo, A. J. A. E., van Dijken, J. H., Veldstra, J. L., Brookhuis, K., de Waard, D., et al. (2021) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2778 · Cited by 10
Premedication with midazolam is more effective by the sublingual than oral route
Lim, T. W., Thomas, E., & Choo, S. M. (1997) · Canadian Journal of Anesthesia/Journal canadien d anesthésie · doi:10.1007/bf03013385 · Cited by 9
(1997) · Annals of Pharmacotherapy · doi:10.1177/106002809703100720 · Cited by 7
Attitudes toward Different Formulations of Psychotropic Drugs
ller, M. J. M. (2006) · American Journal of Drug Delivery · doi:10.2165/00137696-200604010-00004 · Cited by 7
Part I: The Psychopharmacology of Long-Term Aggression—Toward an Evidence-Based Algorithm
Bourget, D. (2002) · Cited by 6
Pharmaceutical applications of 1,4-benzodiazepines
Nikfarjam, Z., Doustkhah, E., Zamani, F., & Brown, R. W. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824516-3.00009-4 · Cited by 9
Pharmacologic Treatment of Agitation
Citrome, L. (2017) · Cambridge University Press eBooks · doi:10.1017/9781316556702.016 · Cited by 5
Nielsen‐Kudsk, F., Jensen, T. S., Magnussen, I., Jakobsen, P., Jensen, P. B., Mondrup, K., & Petersen, T. (1983) · Acta Pharmacologica et Toxicologica · doi:10.1111/j.1600-0773.1983.tb03413.x · Cited by 6
The pharmacokinetics of clotiazepam after oral and sublingual administration to volunteers
Benvenuti, C., Bottà, V., Broggini, M., Gambaro, V., Lodi, F., & Valenti, M. (1989) · European Journal of Clinical Pharmacology · doi:10.1007/bf00562556 · Cited by 5
“Alprazolam [9], lorazepam [ 10 ], and lormetazepam [11] also have comparable absorption and no statistical differences f or Cmax and tm~× after sublingual and oral administration.”
BackgroundSedating Drugs and Neuromuscular Blockade During Mechanical Ventilation
Fraser, G. L. (1992) · JAMA · doi:10.1001/jama.1992.03480130087017 · Cited by 5
Srinivas, N. R. (2012) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-012-1242-5 · Cited by 5
Benzodiazepines in the Home Treatment of Acute Seizures
Akinbi, M. S., & Welty, T. E. (1999) · Annals of Pharmacotherapy · doi:10.1345/aph.17306 · Cited by 4
Lee, K. W., Kim, T. H., Lee, J. B., Kim, K. S., Park, J. B., Gershkovich, P., Yoo, S. D., Shin, S., Shin, B. S., & Kim, S. J. (2018) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2018.05.013 · Cited by 4
Treatment of Generalized Convulsive Status Epilepticus
Shih, T., & Bazil, C. W. (2005) · Humana Press eBooks · doi:10.1385/1-59259-945-1:265 · Cited by 5
“The time to peak plasma concentrations of diazepam and lorazepam may be as long as 90 min after intramuscular injection (31, 32 ).”
BackgroundLumley, J. (1984) · Anaesthesia · doi:10.1111/j.1365-2044.1984.tb08924.x · Cited by 4
Metadata
- Authors
- Greenblatt, D. J., Divoll, M., Harmatz, J. S., & Shader, R. I.
- Affiliations
- Tufts University (US)
- Corresponding author
- Greenblatt, David J.
- Venue
- Journal of Pharmaceutical Sciences
- Publisher
- Elsevier BV
- Published
- 1982-02
- Volume
- 71
- Issue
- 2
- Pages
- 248-252
- ISSN
- 0022-3549 (ISSN-L)
- OpenAlex
- W2143672875
- Cited by
- 134
- References
- 8
- Citations by year
- 2026: 1 · 2024: 2 · 2023: 7 · 2022: 5 · 2021: 3 · 2019: 1 · 2018: 5 · 2017: 2 · 2016: 4 · 2015: 4 · 2014: 6 · 2013: 7 · 2012: 4
- FWCI
- 3.56
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- Journal of Pharmaceutical Sciences (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Anesthesia and Sedative Agents
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Keywords
- lorazepam, sublingual administration, pharmacokinetics, route of administration, intramuscular injection, intravenous administration, oral tablets, absorption half-life, absolute bioavailability, elimination half-life, volume of distribution, drug clearance
- MeSH terms
- Administration, Oral, Adult, Female, Half-Life, Humans, Injections, Intramuscular, Injections, Intravenous, Kinetics, Lorazepam, Male, Mouth Floor, Anti-Anxiety Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.